PRELUDE THERAPEUTICS INC Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
PRELUDE THERAPEUTICS INC (PRLD) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -1.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2025-03-10
- PRELUDE THERAPEUTICS INC effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -1.00%.
- PRELUDE THERAPEUTICS INC effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -1.10%.
- PRELUDE THERAPEUTICS INC effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -0.80%, a 122.86% decline from fiscal 2021.
- PRELUDE THERAPEUTICS INC effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was 3.50%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -1.00% 10-K · filed 2025-03-10 | |
| 2023-12-31 | -1.10% 10-K · filed 2025-03-10 | 1.10% 10-K · filed 2024-02-15 |
| 2022-12-31 | -0.80% 10-K · filed 2024-02-15 | |
| 2021-12-31 | 3.50% 10-K · filed 2023-03-15 | |
| 2020-12-31 | -1.20% 10-K · filed 2022-03-17 | |
| 2019-12-31 | -0.40% 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |